EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nektar Therapeutics's enterprise value is $69.39 Mil.
Nektar Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $90.12 Mil. Therefore, Nektar Therapeutics's EV-to-Revenue for today is 0.77.
The historical rank and industry rank for Nektar Therapeutics's EV-to-Revenue or its related term are showing as below:
NKTR'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.59 Med: 10.13 Max: 55.59
Current: 0.77
During the past 13 years, the highest EV-to-Revenue of Nektar Therapeutics was 55.59. The lowest was -2.59. And the median was 10.13.
NKTR's EV-to-Revenue is ranked better than 88% of 1033
companies
in the Biotechnology industry
Industry Median: 7.63
vs NKTR: 0.77
As of today (2024-04-25), Nektar Therapeutics's stock price is $1.365.
Nektar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.47. Therefore, Nektar Therapeutics's PS Ratio for today is 2.88.
Nektar Therapeutics EV-to-Revenue Historical Data
The historical data trend for Nektar Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nektar Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Nektar Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's EV-to-Revenue falls into.
Nektar Therapeutics's current Enterprise Value is $69.39 Mil.
Nektar Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $90.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics's share price for today is $1.365.
Nektar Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 